Sienna Biopharmaceuticals IncOver The Counter Market:SNNAQ
- LAST PRICE0.0000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.0000
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Sienna Biopharmaceuticals Inc | 30.0 | 0.0x | --- |
FluoroPharma Medical Inc | 3.4K | 0.0x | --- |
OncoSec Medical Inc | 1.2K | 0.0x | --- |
Regnum Corp | 2.3K | 0.0x | --- |
Easton Pharmaceuticals Inc | 1.3K | 0.0x | --- |
Gene Biotherapeutics Inc | 60.0 | 0.0x | --- |
Company Information
Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on bringing scientific innovations to patients whose lives remain burdened by their disease. Its lead candidate from its platform, SNA-120, is an inhibitor of Tropomyosin receptor kinase A (TrkA) for the treatment of psoriasis, as well as the associated pruritus (itch). The Company's second product candidate, SNA-125, is a dual Janus kinase 3 (JAK3)/TrkA inhibitor for the treatment of atopic dermatitis, psoriasis and the associated pruritus. In addition, the Company also offers SNA-001, a silver photo particle technology derived from its Topical Photoparticle Therapy platform.
Contact Information
- Headquarters
- 30699 Russell Ranch Rd Ste 140WESTLAKE VILLAGE, CA, United States 91362-7327
- Phone
- 818-629-2256
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Keith Leonard
- President, Chief Executive Officer, Director
- Frederick Beddingfield
- Chief Financial Officer
- Alexander Azoy
- Vice President, Investor Relations
- Sean Andrews
- General Counsel, Corporate Secretary
- Timothy Andrews
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $30.00 |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 30.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.00 |
Book Value | $1.27 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
